IP Library Granted Patent US 11,209,436
Granted Patent B2
US 11,209,436 · App. 16/799,113 · Granted Dec 28, 2021

Vitro potency assay for protein-based meningococcal vaccines

Inventors: Marzia Giuliani (Siena, IT); Elena Mori (Monteriggioni, IT)
Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
G01N33/577A61K39/095C07K14/22C07K16/1217G01N33/56911C07K2317/33C07K2317/56G01N2333/22
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,209,436
App. No.
16/799,113
Granted
Dec 28, 2021
Kind
B2
Abstract

The invention uses ELISA or similar assays for analysing a meningococcal vaccine. The assay uses antibodies which bind to meningococcal proteins within the vaccine, and in particular monoclonal antibodies which are bactericidal for meningococcus and/or which recognise conformational epitopes within the meningococcal proteins. By performing the assay on a series of dilutions of a test vaccine, and by comparing the results with those obtained using a reference vaccine of known potency, it is possible to determine the relative potency of the test vaccine. This value can be used as a parameter for determining whether a manufactured batch of a vaccine is suitable for release to the public, or whether it has experienced a production failure and so should not be used.

Claims (9)

1. A monoclonal antibody comprising variable regions comprising the amino acid sequences of SEQ ID NO: 21 and SEQ ID NO: 22.

2. The monoclonal antibody of claim 1 , in contact with a batch of vaccine, a bulk of vaccine, or a sample from a batch of vaccine or from a bulk vaccine comprising one or more meningococcal protein immunogens.

3. The monoclonal antibody of claim 2 , wherein the one or more meningococcal protein immunogens are meningococcal Neisseria Heparin Binding Antigen (NHBA), meningococcal factor H binding protein (fHbp), and/or meningococcal Neisseria ) adhesin A (NadA).

4. The monoclonal antibody of claim 3 , wherein the one or more meningococcal protein immunogens is meningococcal fHbp.

5. The monoclonal antibody of claim 3 , wherein the one or more meningococcal protein immunogens are meningococcal NHBA, meningococcal fHbp, and meningococcal NadA.

6. The monoclonal antibody of claim 2 , wherein the sample, the batch of vaccine, or the bulk vaccine further comprises a meningococcal vesicle.

7. The monoclonal antibody of claim 1 , in contact with a secondary antibody labelled with an enzyme.

8. The monoclonal antibody of claim 2 , further in contact with a secondary antibody labelled with an enzyme.

9. The monoclonal antibody of claim 1 , wherein the monoclonal antibody is a murine monoclonal IgG antibody.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 24, 2020
From: GIULIANI, MARZIA; MORI, ELENA
To: NOVARTIS VACCINES AND DIAGNOSTICS SRL
Reel/Frame 051906/0134 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 24, 2020
From: NOVARTIS VACCINES AND DIAGNOSTICS SRL
To: NOVARTIS AG
Reel/Frame 051906/0323 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 24, 2020
From: NOVARTIS AG
To: GLAXOSMITHKLINE BIOLOGICALS SA
Reel/Frame 051906/0435 →
Continuity (3)
Division 14382690
Provisional Application 61608293 · Mar 8, 2012
Related Publication 20200319184A1 · Oct 8, 2020